Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-11-23 19:28 CET (UTC+1h)
 

long half life drug bioequivalence study design [Design Issues]

posted by ssussu - China, 2017-08-16 11:45  - Posting: # 17690
Views: 1,228

Dear all,
I have questions on the BE study design of long half life drug, please kindly give me some advice. According to FDA GL:
You can use Cmax and a suitably truncated AUC to characterize peak and total drug exposure, respectively. For drugs that demonstrate low intrasubject variability in distribution and clearance, you can use an AUC truncated at 72 hours (AUC0-72 hr) in place of AUC0–t or AUC0–inf.
The question is
Should I just need to design the sampling time to 72hr or need to longer than 72hr?
If I just sampling for 72hr, how can I prove the drug is a long half life drug?

Best regards!

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
17,494 Posts in 3,746 Threads, 1,090 registered users;
27 users online (0 registered, 27 guests).

Cave diving is like playing chess
but the king is not made of wood.    Jochen Hasenmayer

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
XHTML/CSS RSS Feed